Results 51 to 60 of about 28,261 (176)
Secreted Nonstructural Protein 3 is a Pathogenic Determinant of Orbivirus
Advanced Science, Volume 13, Issue 42, 28 July 2026.This study uncovers a conserved PIP2‐dependent secretory pathway of orbivirus NS3 that induces vascular leakage. Pharmacological disruption of PIP2‐NS3 interaction significantly reduces viral pathogenicity and provides protective efficacy in murine models, establishing PIP2‐mediated NS3 secretion as both a key virulence determinant and a promising ...
Junyong Guan +11 more
wiley +1 more source
EBOV sGP increases phosphorylation of MEK1/2 and EBOV infectivity in Huh7 cells.
, 2021 (A) Huh7 cells were incubated with 100 μg/ml EBOV sGP, RESTV sGP, or the equivalent amount of CP. After 0, 15, 30, and 60 min incubation at 37°C, phosphorylation of MEK1/2 at Ser217/221 (p-MEK1/2) was assessed by WB analysis.
Andrea Marzi (146489) +3 more
core +1 more source
PLoS ONE, 2023 Introduction A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens ...
Trésor Zola Matuvanga +14 more
doaj
PLoS Pathogens, 2013 We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform based on (a) replication-competent rabies virus (RABV), (b) replication-deficient RABV, or (c) chemically inactivated RABV expressing EBOV glycoprotein (GP). Mouse
Joseph E Blaney +9 more
doaj +1 more source
One Yeast, Sixteen Synthetic Chromosomes, Infinite Possibilities
Yeast, Volume 43, Issue 4, Page 143-158, July 2026.ABSTRACT The evolution of the yeast, Saccharomyces cerevisiae, from a genetically tractable model organism to a chassis for genome‐scale engineering represents one of the most influential trajectories in eukaryotic biology. The Synthetic Yeast Genome Project (Sc2.0) embodies the current height of this trajectory, having now delivered functional ...
Edward Archer +4 more
wiley +1 more source
Susceptibility of different cell types to infection with EBOV.
, 2018 Vero E6 (A, B), Huh 7 (C, D), and MDM (E, F) cells were infected with EBOV/Mak at a range of MOIs. The assay endpoints were 24, 48, 72 or 96 hpi. Following staining with a VP40-antibody, HCI was performed to determine the percentage of EBOV-positive ...
Nicole Deiuliis (4994453) +17 more
core +1 more source
Frontiers in Immunology, 2022 The 2013–2016 Ebola virus (EBOV) epidemic in West Africa was unprecedented in case numbers and fatalities, and sporadic outbreaks continue to arise.
Jack Mellors +21 more
doaj +1 more source
Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery
Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju +3 more
wiley +1 more source
Bioavailability of purified EBOV/SUDV human pAbs in mice.
, 2015 BALB/c mice (N = 10) received a single IP injection of 100 mg/kg of the purified V3 EBOV/SUDV human pAbs. (A) Sera collected from individual mice at the indicated time points after injection were analyzed by standard ELISA for total human IgG using whole-
John M. Dye (131085) +13 more
core +1 more source
TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis.
PLoS Neglected Tropical Diseases, 2019 BackgroundT cell immunoglobulin mucin domain-1 (TIM-1) is a phosphatidylserine (PS) receptor, mediating filovirus entry into cells through interactions with PS on virions.
Bethany Brunton +6 more
doaj +1 more source